When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about ANI Pharmaceuticals (ANIP) .ANI currently has an average brokerage recommendation (ABR) of 1.25 ...

Have you been paying attention to shares of ANI Pharmaceuticals (ANIP) ? Shares have been on the move with the stock up 19.8% over the past month. The stock hit a new 52-week high of $70.5 in the previous session. ANI Pharmaceuticals has gained 22.7% since the start of the year compared to the 6.2% move for the Zacks Medical sector and the 1.3% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it ...

Financial Data and Key Metrics Changes - Total revenue for 2023 was $486.8 million, an increase of 54% over 2022 [7] - Adjusted non-GAAP EBITDA reached a record $133.8 million, up 140% year-over-year [7] - Adjusted non-GAAP earnings per share were $4.71, an increase of 246% from 2022 [7] - Fourth quarter revenues were $131.7 million, a 40% increase over Q4 2022 [16] - Net income available to common shareholders for Q4 2023 was $0.7 million, compared to a net loss of $4.7 million in the prior year [18] Business Line Data and Key Metrics Changes - Cortrophin Gel generated $41.7 million in Q4, a year-over-year increase of 137% [8] - For the full year, Cortrophin sales were $112.1 million, representing year-over-year growth of 169% [8] - The generics business generated $71.8 million in revenue during Q4, an increase of 24% over the last year [13] - Established brands and other revenues were $18.1 million in Q4, a decrease of 3% from the prior year [17] Market Data and Key Metrics Changes - Total ACTH unit volume was up 15% in 2023 compared to 2022 [8] - The overall ACTH category has experienced seven consecutive quarters of year-over-year growth [9] - The generics business maintained a strong compliance track record with successful FDA audits [14] Company Strategy and Development Direction - The company plans to expand its rare disease business through M&A and in-licensing, focusing on assets that overlap with current therapeutic areas [12] - Investment in R&D is prioritized to fuel generics growth through new product launches [33] - The company is adding a second geographical region to its pulmonology sales force and expanding into ophthalmology [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory of Cortrophin Gel, expecting revenues to grow 52% to 61% in 2024 [10] - The overall category outlook for ACTH treatments remains robust, with significant growth opportunities [27] - The company does not anticipate additional benefits from supply tailwinds in 2024 [37] Other Important Information - The company ended Q4 with $221.1 million in cash and generated cash flow from operations of $44.7 million [20] - Total company non-GAAP gross margin is expected to be between 62% and 63% in 2024 [23] Q&A Session Summary Question: What market growth is assumed for Cortrophin in 2024? - Management indicated that the overall category outlook remains robust, with significant growth opportunities in ACTH treatments [27] Question: What is the status of additional rare disease assets? - The company is engaged with multiple companies for potential acquisitions, focusing on both current and new therapeutic areas [29] Question: What are the drivers behind the stronger Cortrophin sales? - Increased volumes, effectiveness of the sales force, and record new patient starts are key drivers [32] Question: How will expenses be allocated between SG&A and R&D? - The company plans to invest in both areas, with a focus on supporting generics growth and expanding the Cortrophin Gel franchise [34] Question: What is the progress in pulmonology and the new 1-ml vial for gout? - There has been positive traction in pulmonology, and optimism surrounds the new 1-ml vial for gout, although it is early in the launch [36]

For the quarter ended December 2023, ANI Pharmaceuticals (ANIP) reported revenue of $131.65 million, up 39.7% over the same period last year. EPS came in at $1.00, compared to $0.76 in the year-ago quarter.The reported revenue represents a surprise of +7.02% over the Zacks Consensus Estimate of $123.02 million. With the consensus EPS estimate being $0.80, the EPS surprise was +25.00%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

Generated quarterly net revenues of $131.7 million, representing year-over-year growth of 39.7%, net income to common shareholders of $0.7 million, GAAP diluted earnings per share of $0.04Delivered adjusted non-GAAP EBITDA of $30.2 million, and adjusted non-GAAP diluted earnings per share of $1.00Rare Disease business delivered Q4 net revenues of $41.7 million, representing quarter-over-quarter growth of 40.4% and year-over-year growth of 137.3%Generated $119.0 million in cash from operating activities duri ...

Employee and Workforce - As of January 2024, the company has 642 employees, an increase from 600 employees in January 2023, with 569 located in the U.S. and 72 in India[61] - Approximately 41% of the company's workforce identified as female, and 45% identified as a person of color or indigenous person as of the end of 2023[63] - The company has a health and safety program focused on continuous improvement and employee engagement, with training provided to new employees[67] Financial Performance - Net revenues for 2023 reached $486.8 million, a significant increase of 54% compared to $316.4 million in 2022[349] - Operating income for 2023 was $47.0 million, a turnaround from an operating loss of $35.3 million in 2022[349] - Net income for 2023 was $18.8 million, compared to a net loss of $47.9 million in 2022, marking a substantial improvement[351] - Basic income per share for 2023 was $0.86, compared to a loss of $3.05 per share in 2022[349] - The company reported a total comprehensive income of $15.5 million for 2023, compared to a comprehensive loss of $32.7 million in 2022[351] Assets and Liabilities - As of December 31, 2023, total assets increased to $904.4 million from $760.1 million in 2022, representing an increase of approximately 19%[345] - Total current assets reached $519.8 million, up from $344.3 million in 2022, reflecting a growth of approximately 51%[345] - The company's total liabilities increased to $446.8 million in 2023 from $421.5 million in 2022, a rise of about 6%[345] - Total stockholders' equity increased to $432.7 million in 2023, up from $313.7 million in 2022, representing a growth of around 38%[345] Cash Flow and Investments - Cash and cash equivalents rose significantly to $221.1 million in 2023, compared to $48.2 million in 2022, marking an increase of over 358%[345] - Operating cash flow for 2023 was $118,959 million, compared to a cash outflow of $31,203 million in 2022[358] - The company reported a net cash outflow of $18,511 million from investing activities in 2023, compared to an outflow of $15,738 million in 2022[358] Debt and Interest Rates - The company has a total net leverage ratio requirement not to exceed 4.75:1.00 under its Credit Agreement, with a stricter limit of 4.50:1.00 applicable until September 30, 2023[321] - The company amended its Credit Agreement in July 2023 to transition from LIBOR to SOFR, with specific credit spread adjustments for different interest periods[322] - The company is exposed to interest rate risk, with a 1% change in interest rates potentially impacting interest expense by approximately $1.6 million for the Term Facility[323] - The interest rate under the Term Facility was 11.46% at December 31, 2023[457] - Total interest expense related to the Term Facility for the year ended December 31, 2023, was $32.5 million, compared to $28.4 million in 2022[463] Research and Development - Research and development expenses increased to $34.3 million in 2023, up 54% from $22.3 million in 2022[349] - The company plans to continue expanding its product offerings and investing in research and development to drive future growth[349] Acquisitions and Strategic Initiatives - The company has made strategic acquisitions, including the acquisition of Novitium, which contributed to revenue growth[354] - The acquisition of Novitium was completed for a total consideration of approximately $206.5 million, including cash, restricted shares, and contingent consideration[440] - Novitium generated revenues of $149.9 million in 2023, up from $90.3 million in 2022, indicating significant growth post-acquisition[444] Environmental and Social Governance - The company is committed to environmental stewardship and has formed an ESG Steering Committee to oversee sustainability initiatives[68] - The company has formed the ANI Rare Disease Patient Assistance Program to provide free medicines to uninsured patients in the U.S.[65] Operational Changes - The company has ceased operations at the Oakville, Ontario manufacturing facility as of March 31, 2023, to streamline operations[363] - The company plans to sell the Oakville facility for approximately $14.2 million USD, with the sale expected to close in March 2024[363] Inventory and Revenue Recognition - The company’s inventory as of December 31, 2023, totaled $111.2 million, an increase from $105.4 million in 2022[470] - Revenue is recognized primarily from sales of generic, rare disease, and established brand pharmaceutical products, with control of products typically transferring to customers upon sale[370] - The company continually adjusts its Average Selling Prices (ASPs) based on chargeback activity and other market factors to reflect actual selling prices[423][432] Financial Controls and Reporting - The company maintained effective internal control over financial reporting as of December 31, 2023, according to the audit opinion[338] - The allowance for credit losses was immaterial as of December 31, 2023, and 2022, indicating a stable credit risk profile[379]

Wall Street analysts forecast that ANI Pharmaceuticals (ANIP) will report quarterly earnings of $0.80 per share in its upcoming release, pointing to a year-over-year increase of 5.3%. It is anticipated that revenues will amount to $123.02 million, exhibiting an increase of 30.6% compared to the year-ago quarter.Over the last 30 days, there has been an upward revision of 16.9% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsi ...

The market expects ANI Pharmaceuticals (ANIP) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to b ...

BAUDETTE, Minn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Leerink Partners Global Biopharma Conference in Miami Beach as follows: Date: Tuesday, March 12, 2024   Time: 2:20 p.m. ET   Webcast: Click Here    To schedule a 1x1 meeting with the Company, please contact your Leerink representative. The live and archived webcast will be ...

Group 1 - ANI Pharmaceuticals (ANIP) closed at $57.03, reflecting a +0.92% change from the previous day's close, outperforming the S&P 500's daily loss of 0.1% [1] - Over the past month, ANI Pharmaceuticals' shares have decreased by 0.41%, underperforming the Medical sector's gain of 2.32% and the S&P 500's gain of 5.78% [1] - The upcoming earnings report is scheduled for February 29, 2024, with projected EPS of $0.78, indicating a 2.63% increase year-over-year, and revenue expected to be $119.38 million, a 26.69% increase year-over-year [1] Group 2 - Recent changes to analyst estimates for ANI Pharmaceuticals reflect short-term business trends, with upward revisions indicating analysts' positive outlook on the company's operations [2] - The Zacks Rank system, which assesses estimate changes, currently ranks ANI Pharmaceuticals at 3 (Hold), with the consensus EPS estimate remaining stagnant over the past month [2] - Stocks rated 1 in the Zacks Rank have historically produced an average annual return of +25% since 1988 [2] Group 3 - ANI Pharmaceuticals has a Forward P/E ratio of 13.92, which is a discount compared to the industry's average Forward P/E of 21.34 [3] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 97, placing it in the top 39% of over 250 industries [3] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [3]